The Neurotrauma Assessment Test (NTAT™) is a mass spectrometry-based diagnostic that provides definitive evidence of traumatic brain injury (TBI) injury at any stage, enables progression monitoring, and delivers mechanistically grounded insight into injury severity and the risk of long-term cognitive impairment.

We don’t just provide a test – we design and oversee the end-to-end system around it: credentialing and coordinating providers, embedding utilization protocols, integrating reporting dashboards, and assuming financial and administrative risk. This ensures advanced diagnostics like NTAT™ create not just clinical value, but measurable system-wide impact.

NTAT™ quantifies concentrations of four clinically validated neurotrauma-related proteins – Glial Fibrillary Acidic Protein (GFAP), Ubiquitin C-terminal Hydrolase L1 (UCH-L1), S100ß, and Neurofilament-Heavy Chain (NF-H) – alongside two functional genetic markers known to influence post-TBI outcomes: Apolipoprotein E (APOE) and Methylenetetrahydrofolate Reductase (MTHFR). This multiplexed approach captures complementary dimensions of traumatic brain injury, integrating biochemical evidence of acute and chronic neurotrauma with genetic predisposition data.

By embedding NTAT™ science into an evidence-based clinical pathway and technology-assisted management platform, we deliver collaborative, consistent, and connected care – bridging one-patient-at-a-time services with population-wide analytic medicine. Integrating advanced diagnostics like NTAT™ into a managed pathway for your network closes the gap between laboratory-developed tests and real-world clinical practice.

Kevin Rosenblatt, M.D., Ph.D., and Peter Bryant-Greenwood, M.D., the developers and laboratory directors behind NTAT™, serve as medical directors at BioConnetiX, working directly with your network on pathway design and decision-support protocols. BioConnetiX then builds the system to manage the pathway. To safeguard impartiality, medical directors and laboratory owners hold no ownership in BioConnetiX, and BioConnetiX holds no stake in the testing laboratories. Independent subspecialist pathologists, also with no ownership ties, conduct utilization review to ensure every test is applied with precision and value.

BioConnetiX assumes the financial risk – covering direct costs of laboratory testing, utilization review, and networked providers – transforming world-class science into lower costs and better outcomes through standardized management and controlled spend. The NTAT™ pathway can be managed entirely within the BioConnetiX provider network (neurologist network manages clinical workup and care plan via telehealth) – or integrated into your primary care network, with multidisciplinary expertise always just a call – or a click – away.

The current standard of care for traumatic brain injury (TBI) diagnostics is centered almost exclusively on the acute post-injury period, typically within the first 24 to 72 hours. Conventional clinical tools – which include symptom inventories, neurocognitive screens (e.g., MACE, MoCA), and structural imaging (CT, MRI) – are designed to detect gross abnormalities, intracranial bleeding, or acute functional impairments. However, these tools exhibit low sensitivity for mild-to-moderate TBI (mmTBI), and their diagnostic utility rapidly diminishes beyond the acute phase. As a result, the vast majority of TBI cases – especially those without overt radiographic findings – go undetected or misclassified, resulting in avoidable and often long-term neurological compromise.

Moreover, once the immediate injury window has passed, no clinically validated method exists to definitively confirm prior TBI, assess cumulative exposure, or determine recovery status. This not only impairs timely intervention but also precludes effective longitudinal care, contributing to persistent post-concussive symptoms (PCS), cognitive and functional decline, and elevated long-term disability rates.

BioConnetiX closes this diagnostic blind spot. NTAT™ provides objective confirmation across any phase of injury evolution and recovery: Acute (0–72 hours post-injury), Post-Acute (4 days to 6 weeks post-injury), and Chronic (6 weeks to more than 5 years post-injury), while our managed care framework ensures those results are translated into standardized, protocol-driven care that reduces cost variability and prevents patients from slipping through gaps in the system.

• Objective Diagnosis – Delivers diagnostic accuracy, replacing subjective inputs with objective biomarkers to enable confident, evidence-based decisions
• Risk Stratification – Generates risk score (low, medium, high) for prolonged cognitive impairment, supporting targeted interventions that optimize recovery outcomes
• Longitudinal Monitoring – Enables serial tracking of neurological status to confirm injury resolution, detect ongoing neurodegeneration, and assess cumulative exposure
• Integrated Intelligence – Operationalizes a digital clinical framework for efficient, consistent, and connected multidisciplinary care. This ensures the entire network operates from one consistent playbook
• Public Health Advantage – Population-level data can inform AI/ML analysis, risk pattern identification, and scalable prevention strategies – reducing preventable casualties and system-wide costs